Status:
UNKNOWN
Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD
Lead Sponsor:
University Hospital, Mahdia
Conditions:
Acute Exacerbation Copd
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
This study assess whether a procalcitonin guided antibiotic therapy can reduce significantly unnecessary antibiotic prescription during severe exacerbation of COPD requiring mechanical ventilation wit...
Detailed Description
Recently, procalcitonin gained interest as the most reliable biomarker in predicting bacterial origin in low respiratory tract infections and sepsis. Procalcitonin was shown to be non-inferior to sta...
Eligibility Criteria
Inclusion
- Patients \> 40 years old who consent to the study protocol
- COPD diagnosis based on GOLD guidelines
Exclusion
- Patients who did not consent
- Asthma
- Malignancy
- Immunocompromised
- Survival for at least 1 year is unlikely
- Patients already enrolled in this study
Key Trial Info
Start Date :
October 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03440060
Start Date
October 5 2017
End Date
December 31 2020
Last Update
May 13 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tilouche Nejla
Mahdia, Tunisia, 5100